72 results
8-K
EX-99.1
ANNX
Annexon Inc
25 Jun 24
Annexon Presented Additional Positive Phase 3 Results for ANX005 C1q-Targeted Immunotherapy in Guillain-Barré Syndrome at the 2024 PNS Annual Meeting
5:14pm
of Disability and Muscle Strength
Single Infusion of ANX005 was Generally Well-Tolerated with Safety Profile Similar to Placebo
Data Reinforce Potential
8-K
EX-1.1
ANNX
Annexon Inc
7 Jun 24
Annexon Announces Pricing of $125 Million Underwritten Public Offering
4:42pm
requirements relating to pollution or the protection of human health or safety, the environment, natural resources, hazardous or toxic substances
424B5
ANNX
Annexon Inc
6 Jun 24
Prospectus supplement for primary offering
9:57pm
volunteers designed to evaluate the safety, tolerability, pharmacokinetics, or PK, and pharmacodynamics, or PD, ANX1502 was generally well tolerated across … dose, or MAD, clinical trial in healthy volunteers designed to evaluate the safety, tolerability, pharmacokinetics, or PK, and pharmacodynamics, or PD
424B5
ANNX
Annexon Inc
4 Jun 24
Prospectus supplement for primary offering
5:21pm
, and multiple-ascending dose, or MAD, clinical trial in healthy volunteers designed to evaluate the safety, tolerability, pharmacokinetics, or PK … , clinical trial in healthy volunteers designed to evaluate the safety, tolerability, pharmacokinetics, or PK, and pharmacodynamics, or PD, ANX1502
8-K
EX-99.2
ANNX
Annexon Inc
4 Jun 24
Annexon Announces Positive Topline Results from Pivotal Phase 3 Trial for First-in-Class C1q Blocking Antibody ANX005 in Guillain-Barré Syndrome
7:05am
to investigational use, and no representation is made as to their safety or effectiveness for the purposes for which they are being investigated … in a better state of health meaningful benefit on multiple placebo at all timepoints across Safety data was similar to on GBS-DS at Week 8 outcome measures
8-K
iv9mkmw1iis6utm9ad
4 Jun 24
Annexon Announces Positive Topline Results from Pivotal Phase 3 Trial for First-in-Class C1q Blocking Antibody ANX005 in Guillain-Barré Syndrome
7:05am
8-K
EX-99.1
kn7suw w2l
4 Jun 24
Annexon Announces Positive Topline Results from Pivotal Phase 3 Trial for First-in-Class C1q Blocking Antibody ANX005 in Guillain-Barré Syndrome
7:05am
8-K
EX-99.1
dnqlh0z7ww 3un70og
13 May 24
Annexon Reports First Quarter 2024 Financial Results and Key Anticipated Milestones
4:05pm
8-K
EX-99.1
1alfla6f1pbnccw1wzcp
7 May 24
Other Events
4:05pm
424B5
v8301q 9x
5 Apr 24
Prospectus supplement for primary offering
4:07pm
8-K
EX-99.1
pqlxaok9
26 Mar 24
Annexon Reports Fourth Quarter and Year-End 2023 Financial Results and Key Anticipated Milestones
4:05pm
8-K
EX-99.1
moc3u2tyo1yks55c9v
4 Mar 24
Regulation FD Disclosure
5:25pm
8-K
EX-99.1
jvka2fsnlwi 48ou
8 Jan 24
Regulation FD Disclosure
4:09pm
8-K
EX-1.1
m383cfv
21 Dec 23
Annexon Announces Pricing of $125.0 Million Underwritten Public Offering of Common Stock
4:09pm
424B5
rvwfl qko4tq9ls
21 Dec 23
Prospectus supplement for primary offering
4:05pm
8-K
l8o6vm
20 Dec 23
Regulation FD Disclosure
5:17pm